DGIdb - DIHYDROERGOTAMINE Drug Record

DIHYDROERGOTAMINE chembl:CHEMBL1732 Approved

Alternate Names:

DIHYDROERGOTAMINE
MAP0004
MAP-0004
DHE111
9,10-DIHYDROERGOTAMINE
5'-BENZYL-12'-HYDROXY-2'-METHYL-3',6',18-TRIOXO-9,10-DIHYDROERGOTAMAN
DIHYDROERGOTAMIN
DIIDROERGOTAMINA
MIGRANAL®
9,10-DIHYDRO-12'-HYDROXY-2'-METHYL-5'-(PHENYLMETHYL)ERGOTOMAN-3',6',18-TRIONE
(2R,4R,7R)-N-[(1S,2S,4R,7S)-7-BENZYL-2-HYDROXY-4-METHYL-5,8-DIOXO-3-OXA-6,9-DIAZATRICYCLO[7.3.0.02,6]DODECAN-4-YL]-6-METHYL-6,11-DIAZATETRACYCLO[7.6.1.02,7.012,16]HEXADECA-1(16),9,12,14-TETRAENE-4-CARBOXAMIDE
DIHIDROERGOTAMINA
D.H.E. 45®
DIHYDROERGOTAMINUM
rxcui:3418
pubchem.compound:10531
chembl:CHEMBL1732
chemidplus:511-12-6
drugbank:00320

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antimigraine agent
Year of Approval	1946
Drug Class	anti-migraine agents

(1 More Sources)

Publications:

Willems et al., 1999, Pharmacological evidence that alpha1-and alpha2-adrenoceptors mediate vasoconstriction of carotid arteriovenous anastomoses in anaesthetized pigs., Br. J. Pharmacol.
Villalón et al., 2004, 5-HT1B receptors and alpha 2A/2C-adrenoceptors mediate external carotid vasoconstriction to dihydroergotamine., Eur. J. Pharmacol.
Buzzi et al., 1991, Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine., Cephalalgia
Pauwels et al., 1998, Interaction of 5-HT1B/D ligands with recombinant h 5-HT1A receptors: intrinsic activity and modulation by G-protein activation state., Naunyn Schmiedebergs Arch. Pharmacol.
Yu et al., 1996, 5-Carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl -tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors., Mol. Pharmacol.
Silberstein et al., 2003, Ergotamine and dihydroergotamine: history, pharmacology, and efficacy., Headache
Lesage et al., 1998, Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines., Br. J. Pharmacol.
Buzzi et al., 1992, The trigemino-vascular system and migraine., Pathol. Biol.
Buzzi et al., 1992, 5-Hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the rat dura mater after trigeminal stimulation., Brain Res.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Hoyer et al., 1992, "5-HT1R" or 5-HT1D sites? Evidence for 5-HT1D binding sites in rabbit brain., Naunyn Schmiedebergs Arch. Pharmacol.

DIHYDROERGOTAMINE HTR1D

Interaction Score: 4.84

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name MAP-0004, TEMPO Migraine,Levadex

Novel drug target Established target

Trial Name MT 300

PMIDs:
14744615 12558771 9605573 1379707 1324091 11752352 1407010

Sources:
TdgClinicalTrial TEND
DIHYDROERGOTAMINE HTR1B

Interaction Score: 2.25

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name MT 300

Novel drug target Established target

Trial Name MAP-0004, TEMPO Migraine,Levadex

PMIDs:
10455274 14744615 1660351 9650800 8622623

Sources:
TdgClinicalTrial
DIHYDROERGOTAMINE DRD1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DIHYDROERGOTAMINE DRD2

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
DIHYDROERGOTAMINE MAPT

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: DIHYDROERGOTAMINE
- Version: 01-August-2011
Alternate Names:

DIHYDROERGOTAMINE Primary Drug Name

Drug Info:

Drug Class anti-migraine agents

Year of Approval 1946

Publications:
TdgClinicalTrial: DIHYDROERGOTAMINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antimigraine agent

Drug Class Small Molecule

FDA Approval approved

Publications:
TTD: Dihydroergotamine
- Version: 2020.06.01
Alternate Names:

D0V3ZA TTD Drug ID

Drug Info:

Publications:
DTC: DIHYDROERGOTAMINE
- Version: 02-September-2020
Alternate Names:

CHEMBL1732 ChEMBL Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1732
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	MAP-0004, TEMPO Migraine,Levadex
Novel drug target	Established target
Trial Name	MT 300

DIHYDROERGOTAMINE Drug Record

DIHYDROERGOTAMINE chembl:CHEMBL1732 Approved

Alternate Names:

Drug Info:

Publications:

DIHYDROERGOTAMINE HTR1D

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name MAP-0004, TEMPO Migraine,Levadex Novel drug target Established target Trial Name MT 300

PMIDs: 14744615 12558771 9605573 1379707 1324091 11752352 1407010

Sources: TdgClinicalTrial TEND

DIHYDROERGOTAMINE HTR1B

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name MT 300 Novel drug target Established target Trial Name MAP-0004, TEMPO Migraine,Levadex

PMIDs: 10455274 14744615 1660351 9650800 8622623

Sources: TdgClinicalTrial

DIHYDROERGOTAMINE DRD1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

DIHYDROERGOTAMINE DRD2

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

DIHYDROERGOTAMINE MAPT

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

TEND: DIHYDROERGOTAMINE

Alternate Names: DIHYDROERGOTAMINE Primary Drug Name

Drug Info: Drug Class anti-migraine agents Year of Approval 1946

Publications:

TdgClinicalTrial: DIHYDROERGOTAMINE

Alternate Names:

Drug Info: Drug Indications antimigraine agent Drug Class Small Molecule FDA Approval approved

Publications:

TTD: Dihydroergotamine

Alternate Names: D0V3ZA TTD Drug ID

Drug Info:

Publications:

DTC: DIHYDROERGOTAMINE

Alternate Names: CHEMBL1732 ChEMBL Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1732

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name MAP-0004, TEMPO Migraine,Levadex

Novel drug target Established target

Trial Name MT 300

PMIDs:
14744615 12558771 9605573 1379707 1324091 11752352 1407010

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name MT 300

Novel drug target Established target

Trial Name MAP-0004, TEMPO Migraine,Levadex

PMIDs:
10455274 14744615 1660351 9650800 8622623

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

DIHYDROERGOTAMINE Primary Drug Name

Drug Info:

Drug Class anti-migraine agents

Year of Approval 1946

Drug Info:

Drug Indications antimigraine agent

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

D0V3ZA TTD Drug ID

Alternate Names:

CHEMBL1732 ChEMBL Drug ID